[Treatment of acute schizophrenic psychosis with beta-adrenergic blocking agents (author's transl)].
D000208:Acute Disease; D000319:Adrenergic beta-Antagonists / Q000494:pharmacology; D000328:Adult; D001794:Blood Pressure / Q000187:drug effects; D002389:Catatonia / Q000188:drug therapy; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D006973:Hypertension / Q000139:chemically induced; D008297:Male; D010096:Oxprenolol / Q000009:adverse effects / Q000627:therapeutic use*; D011433:Propranolol / Q000009:adverse effects / Q000627:therapeutic use*; D011605:Psychoses, Substance-Induced / Q000209:etiology; D012075:Remission, Spontaneous; D012559:Schizophrenia / Q000188:drug therapy*; D012562:Schizophrenia, Disorganized / Q000188:drug therapy; D012893:Sleep Wake Disorders / Q000139:chemically induced; D013894:Thirst / Q000187:drug effects
D000319:Adrenergic beta-Antagonists; D010096:Oxprenolol; D011433:Propranolol
Behandlung von akuten schizophrenen Psychosen mit Beta-Receptoren-Blockern